Permanent Atrial fibriLLAtion Outcome Study Using Dronedarone on Top of Standard Therapy (PALLAS)

This study has been terminated.

(The study was stopped because of safety concerns)

Sponsor:

Information provided by (Responsible Party):

Sanofi

ClinicalTrials.gov Identifier:

NCT01151137

First received: June 22, 2010

Last updated: October 23, 2012

Last verified: October 2012

History of Changes

Results First Received: September 14, 2012

Study Type:	Interventional
Study Design:	Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Triple (Participant, Investigator, Outcomes Assessor); Primary Purpose: Treatment
Condition:	Atrial Fibrillation
Interventions:	Drug: Dronedarone Drug: Placebo (for Dronedarone)

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Recruitment initiated in July 2010 was discontinued on July 6, 2011 upon recommendations of the Data Monitoring Committee due to an increased number of observed cardiovascular events in the Dronedarone group. The common study end date [CSED] was defined as July 15, 2011. At that time 494 sites in 37 countries had enrolled at least one patient.

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations

Recruitment initiated in July 2010 was discontinued on July 6, 2011 upon recommendations of the Data Monitoring Committee due to an increased number of observed cardiovascular events in the Dronedarone group. The common study end date [CSED] was defined as July 15, 2011.

At that time 494 sites in 37 countries had enrolled at least one patient.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Assignment to groups was done centrally using an Interactive Voice Response System [IVRS] or an Interactive Web Response System [IWRS] in a 1:1 ratio. A total of 3236 participants were randomized at 489 sites (instead of 10800 as initially planned). The median duration of their participation in the study was 3.5 months.

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment

Assignment to groups was done centrally using an Interactive Voice Response System [IVRS] or an Interactive Web Response System [IWRS] in a 1:1 ratio.

A total of 3236 participants were randomized at 489 sites (instead of 10800 as initially planned). The median duration of their participation in the study was 3.5 months.

Reporting Groups

	Description
Placebo	Placebo twice daily until the CSED (median treatment duration of 87.5 days)
Dronedarone	Dronedarone 400 mg twice daily until the CSED (median treatment duration of 74 days)

Participant Flow: Overall Study

	Placebo	Dronedarone
STARTED	1617	1619
Treated	1610 ^[1]	1613
Discontinued Treatment	171	342
COMPLETED	1601	1591
NOT COMPLETED	16	28
Death	15	27
Lost to Follow-up	1	1

^[1]	One participant randomized to the placebo group received Dronedarone for 7 days by mistake

Baseline Characteristics

Hide Baseline Characteristics

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups

	Description
Placebo	Placebo twice daily until the CSED (median treatment duration of 87.5 days)
Dronedarone	Dronedarone 400 mg twice daily until the CSED (median treatment duration of 74 days)
Total	Total of all reporting groups

Baseline Measures

Placebo

Dronedarone

Total

Overall Participants Analyzed
[Units: Participants]

1617

1619

3236

Age
[Units: Years]
Mean (Standard Deviation)

75.0 (5.9)

Gender
[Units: Participants]

Female

577

568

1145

Male

1040

1051

2091

Region of Enrollment ^[1]
[Units: Participants]

North America

281

266

547

South America

227

236

463

Western Europe

459

475

934

Eastern Europe

495

488

983

Asia

100

Rest of the word

102

107

209

^[1]

Regions were defined as follows:

North America: Canada, United States
South America: Argentina, Brazil, Chile, Mexico
Western Europe: Austria, Belgium, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Spain, Sweden, Switzerland, United Kingdom
Eastern Europe: Bulgaria, Czech Republic, Hungary, Poland, Romania, Russian Federation, Slovakia, Ukraine Asia: Hong Kong, Republic of Korea, Malaysia, Singapore, Taiwan Rest of the World: Australia, Israel, New zealand, South Africa

Permanent atrial fibrillation [AF] history
[Units: Participants]

6 months to 2 years

490

498

988

> 2 years

1124

1119

2243

Unknown

CHADS2 Score ^[1]
[Units: Participants]

< 2

172

191

363

≥ 2

1444

1427

2871

Unavailable

^[1]

CHADS2 is a risk-prediction score ranging from 0 to 6 used estimate Stroke Risk in Atrial Fibrillation patients.

CHADS2 score is obtained by adding together the points that correspond to the conditions that are present:

C: Congestive Heart Failure history: 1 point
H: Hypertension history: 1 point
A: Age ≥75 years: 1 point
D: Diabetes Mellitus history: 1 point
S: Stroke symptoms previously or Transient Ischemic Attack [TIA]: 2 points

New York Heart Association [NYHA] class ^[1]
[Units: Participants]

No congestive heart failure [CHF]

535

512

1047

NYHA Class I

209

234

443

NYHA Class II

749

732

1481

NYHA Class III

124

141

265

^[1]

NYHA classification is a functional classification that places the patient in one of 4 categories, based on how much he/she is limited during physical activity:

Class I: no limitation of activities; the patient suffers no symptoms from ordinary activities.
Class II: slight, mild limitation of activity; the patient is comfortable with rest or with mild exertion.
Class III: marked limitation of activity; the patient is comfortable only at rest.
Class IV: complete rest, confined to bed or chair; any physical activity brings on discomfort and symptoms occur at rest.

Outcome Measures

Show All Outcome Measures

1. Primary:

Overview of the Two Co-primary Outcomes [ Time Frame: From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year) ]

Show Outcome Measure 1

2. Primary:

Time to First Co-primary Outcome (Cumulative Incidence Function) [ Time Frame: From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year) ]

Show Outcome Measure 2

3. Primary:

Time to Second Co-primary Outcome (Cumulative Incidence Function) [ Time Frame: From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year) ]

Show Outcome Measure 3

4. Secondary:

Deaths [ Time Frame: From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year) ]

Show Outcome Measure 4

5. Secondary:

Time to Cardiovascular Death (Cumulative Incidence Function) [ Time Frame: From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year) ]

Show Outcome Measure 5

6. Other Pre-specified:

Overview of Cardiovascular Events [ Time Frame: From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year) ]

Show Outcome Measure 6

7. Other Pre-specified:

Overview of Adverse Events [AE] [ Time Frame: from first study drug intake up to 10 days after the last study drug intake ]

Show Outcome Measure 7

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

Limitations and Caveats

Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Given that the study was prematurely discontinued after 3236 patients were randomized (30% of the initial planned number), p-values were provided for information without any adjustment for multiplicity.

More Information

Hide More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

The agreement is:

The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.

The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.

Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.

Restriction Description:

If no publication has occurred within 12 months after trial completion, the investigator can present or publish trial results. A copy is submitted to the sponsor for review and comment at least 30 days in advance of any presentation or submission for publication.

The sponsor can require to delay the communication for a period not exceeding 90 days to allow for filing a patent application or such other measures as sponsor deems appropriate to establish and preserve its proprietary rights.

Results Point of Contact:

Name/Title: Trial Transparency Team
Organization: sanofi-aventis
e-mail: Contact_US@sanofi.com

Publications of Results:

Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, Amerena J, Atar D, Avezum Á, Blomström P, Borggrefe M, Budaj A, Chen SA, Ching CK, Commerford P, Dans A, Davy JM, Delacrétaz E, Di Pasquale G, Diaz R, Dorian P, Flaker G, Golitsyn S, Gonzalez-Hermosillo A, Granger CB, Heidbüchel H, Kautzner J, Kim JS, Lanas F, Lewis BS, Merino JL, Morillo C, Murin J, Narasimhan C, Paolasso E, Parkhomenko A, Peters NS, Sim KH, Stiles MK, Tanomsup S, Toivonen L, Tomcsányi J, Torp-Pedersen C, Tse HF, Vardas P, Vinereanu D, Xavier D, Zhu J, Zhu JR, Baret-Cormel L, Weinling E, Staiger C, Yusuf S, Chrolavicius S, Afzal R, Hohnloser SH; PALLAS Investigators. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med. 2011 Dec 15;365(24):2268-76. doi: 10.1056/NEJMoa1109867. Epub 2011 Nov 14. Erratum in: N Engl J Med. 2012 Feb 16;366(7):672.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Hohnloser SH, Halperin JL, Camm AJ, Gao P, Radzik D, Connolly SJ; PALLAS investigators. Interaction between digoxin and dronedarone in the PALLAS trial. Circ Arrhythm Electrophysiol. 2014 Dec;7(6):1019-25. doi: 10.1161/CIRCEP.114.002046. Epub 2014 Nov 6.

Responsible Party:	Sanofi
ClinicalTrials.gov Identifier:	NCT01151137 History of Changes
Other Study ID Numbers:	EFC11405 2010-019791-73 ( EudraCT Number ) U1111-1116-5566 ( Other Identifier: UTN )
Study First Received:	June 22, 2010
Results First Received:	September 14, 2012
Last Updated:	October 23, 2012

To Top